Pfizer enrolled 44,000 people across 270 clinical sites in phase 3 clinical trials for the Pfizer/BioNTech Comirnaty vaccine. The largest of these sites by far was number 1231 in Buenos Aires, under the direction of the paediatric infectious diseases specialist Fernando Polack. The Argentine operation appears to have been plagued by substantial irregularities and is the subject of an ongoing inquiry by the Argentinian parliament.
Before getting to the dodgy trial documentation, it’s worth recalling the conditions under which Pfizer gained approval for its “vaccine” in Argentina.
In 2020, when Pfizer requested the National Administration of Medicines, Food and Medical Technology (“ANMAT”) to authorise the distribution of its vaccine in Argentina, Minister of Health Ginés González García said:
ANMAT “requires all the documentation of the studies that have been done” to authorise it, although he was hopeful given that said medication had its approval in England.
“If they did it in England, they have comfortably everything they have to have.”
Regarding the process that will now take place at ANMAT compared to what happened in England, the official said “regulatory agencies have more or less the same requirements.”
The Minister of Health stated that, unlike other medicinal products, Pfizer requested “a faster authorisation for pandemic reasons.”